Meningitis, Meningococcal
Conditions
Brief summary
This study is a randomized, double-blinded, and controlled phase III clinical trial of the Group A and C meningococcal polysaccharide vaccine to evaluate the safety and immunogenicity of the vaccine in healthy infants aged 2-6 years.
Detailed description
This study was divided into two stages. The first stage study was an early safety assessment study among 80 subjects. The first stage study was conducted gradually in 20 subjects aged 18-50 years, 20 subjects aged 7-17 years, and 40 subjects aged 2-6 years. The second phase was a randomized, double-blind, controlled, non-inferiority phase III clinical trial in 1200 healthy infants aged 2-6 years, to evaluate the immunogenicity and safety of the experimantal vaccine after immunization.
Interventions
BIOLOGICALExperimental Group A and C meningococcal polysaccharide vaccine
One dose of Experimental Group A and C meningococcal polysaccharide vaccine
BIOLOGICALControl Group A and C meningococcal polysaccharide vaccine
One dose of Control Group A and C meningococcal polysaccharide vaccine
Sponsors
Yunnan Center for Disease Control and Prevention
Wei Cun
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
2 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* The First stage study (An early safety assessment study): * 18-50 years group: * Inclusion Criteria: 1. Healthy adults aged 18 to 50 years. 2. Proven legal identity. 3. Participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required. 4. Participants should be able to communicate well with investigators, understand and comply with the requirements of this trial. 5. Axillary temperature ≤37.0℃. *
Exclusion criteria
1. Contraindications for vaccination. 2. History of allergy to vaccines or drugs. 3. History of Epidemic Cerebrospinal Meningitis. 4. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months. 5. Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine within 3 years. 6. Immunization with any vaccine within 30 days. 7. Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy. 8. History of abnormal clinical manifestations and serious diseases to be excluded, including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bones and other system diseases, and a history of malignant tumors. 9. Those who developed acute disease or acute attack of chronic disease. 10. Surgical removal of spleen or other important organs for any reason. 11. History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection. 12. Blood products such as immunoglobulin were received within 30 days before vaccination. 13. Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form). 14. Those who participated in other clinical studies. 15. Participants who have a positive pregnancy test, or are breastfeeding, or plan to become pregnant, or plan to donate sperm or eggs from the screening to 12 months after the second vaccination. 16. Any other situations judged by investigators as not suitable for participating in this study. * 7-17 years group: * Inclusion Criteria 1. Healthy volunteer aged 7 to 17 years. 2. Proven legal identity. 3. Participants and their legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required. 4. Participants and their legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial. 5. Axillary temperature ≤37.0℃. *
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Seroconversion rate of Group A meningococcal bactericidal antibody | 28 days after vaccination | Seroconversion rate of Group A meningococcal bactericidal antibody at day 28 after vaccination |
| Seroconversion rate of Group C meningococcal bactericidal antibody | 28 days after vaccination | Seroconversion rate of Group C meningococcal bactericidal antibody at day 28 after vaccination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serious adverse events | 6 months after the second vaccination | Occurence of Serious adverse events after vaccination |
| GMT of Group C meningococcal bactericidal antibody | 28 days after the second vaccination | GMT of Group C meningococcal bactericidal antibody at day 28 after the second vaccination |
| GMT of Group A meningococcal bactericidal antibody | 28 days after the second vaccination | GMT of Group A meningococcal bactericidal antibody at day 28 after the second vaccination |
| Adverse reactions/events rate | 7 days after vaccination | Occurence of adverse reactions/events after vaccination |
Other
| Measure | Time frame | Description |
|---|---|---|
| GMT of IgG antibody against Hepatitis A | 28 days after the second vaccination | GMT of IgG antibody against Hepatitis A at day 28 after vaccination |
| Seropositive rate of IgG antibody against Hepatitis A | 28 days after the second vaccination | Seropositive rate of IgG antibody against Hepatitis A at day 28 after vaccination |
Countries
China
Contacts
Primary ContactWei Cun, Doctor
Outcome results
None listed